Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004582 · ClinicalTrials.gov registry record · Phase 2
ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past
A Phase 2 study of HIV Infections, sponsored by ViRx.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00004582: Completed Phase 2 study of HIV Infections, sponsored by ViRx.
NCT00004582 is a Phase 2 study of HIV Infections that has completed, run by ViRx. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004582, a Phase 2 study of HIV Infections, has completed, sponsored by ViRx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
The purpose of this study is to see if ABT-378/ritonavir plus efavirenz is safe and effective in lowering the amount of HIV in the blood of patients who have been treated with more than 1 protease inhibitor (PI).
Conditions Studied
Interventions
- DRUG Efavirenz
- DRUG Lopinavir/Ritonavir
Study Locations (1)
California
- ViRx Inc - San Francisco
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004582
The ClinicalTrials.gov registry entry for NCT00004582 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is ViRx, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Efavirenz is the first listed.
NCT00004582 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00004582 about?
NCT00004582 is a clinical study titled "ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past". The purpose of this study is to see if ABT-378/ritonavir plus efavirenz is safe and effective in lowering the amount of HIV in the blood of patients who have been treated with more than 1 protease inhibitor (PI).
What is the current status of trial NCT00004582?
This trial is currently completed. It is a Phase 2 study.
What conditions does trial NCT00004582 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00004582?
The interventions under investigation include: Efavirenz (DRUG), Lopinavir/Ritonavir (DRUG).
Who is sponsoring clinical trial NCT00004582?
This trial is sponsored by ViRx, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004582 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.